A Phase 3 clinical trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682Grazoprevir/Ruzasvir) in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 3 Infection (naive or P/I experienced, non-cirrhotic or compensated cirrhosis); 12 w
Starting April 2012, we are doing Hepatitis C Antibody Testing! Who should be tested? http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm?s_cid=rr6104a1_w The cost is $25 (cash or check) and the results will be back within 24-48 business hours. All testing is confidential.
Takeda Pharmaceuticals is conducting a clinical research study evaluating people who have Crohn's disease. The purpose of this study is to learn more about the effectiveness and safety of vedolizumab subcutaneous (SC) injection compared to placebo SC injection in people with moderately to severely active Crohn's disease.
Upon completion of this clinical research study, you may be eligible to participate in the vedolizumab Open Label Extension study.
For more information, call us at 918-513-3490.
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease.
A Randomized, Double-blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects with Ulcerative Colitis.
You must be diagnosed with UC for at least 6 months.
You have moderately to severely active UC.
Your UC is no longer responding to UC medications or no longer able to take your UC medications.
Placebo controlled study to evaluate the safety of a drug compared to placebo for induction and maintenance therapy with Moderate to severe UC. This is a JAK Inhibitor, which is an oral compound.
Oral daily dosing for subjects with NASH Fibrosis, not cirrhosis. Fibroscan will be performed. 72 week treatment period and additional double-blind long term treatment for up to 3 additional years.
Multicenter, Randomized, Double-blind, Placebo Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis
Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Cenicriviroc "CVC" for the treatment of liver Fibrosis (F2-F3) in adults with NASH.